These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067 [TBL] [Abstract][Full Text] [Related]
6. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura. Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376 [TBL] [Abstract][Full Text] [Related]
7. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285 [TBL] [Abstract][Full Text] [Related]
8. A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy. Nikolaou M; Karakantza M; Adonakis G; Theodorou G; Zoumbos N; Decavalas G Med Pregl; 2012; 65(9-10):436-9. PubMed ID: 23214340 [TBL] [Abstract][Full Text] [Related]
15. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059 [TBL] [Abstract][Full Text] [Related]
16. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI). Cid J; Pérez-Valencia AI; Torrente MÁ; Ávarez-Larrán A; Díaz-Ricart M; Esteve J; Lozano M Transfus Apher Sci; 2021 Feb; 60(1):103011. PubMed ID: 33221124 [TBL] [Abstract][Full Text] [Related]
17. [Successful treatment with cyclosporine in a patient with rituximab-refractory thrombocytopenic purpura]. Nato Y; Nagaharu K; Okano M; Suzuki K; Matsumoto T; Tawara I Rinsho Ketsueki; 2021; 62(3):176-179. PubMed ID: 33828010 [TBL] [Abstract][Full Text] [Related]
18. Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura. Pavenski K; Huang SS; Patriquin CJ Expert Rev Hematol; 2021 Nov; 14(11):1027-1040. PubMed ID: 34747320 [TBL] [Abstract][Full Text] [Related]
19. Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab. Krecak I; Medic MG; Gveric-Krecak V; Roncevic P; Bašić Kinda S; Babel J; Radonic R Acta Clin Belg; 2020 Oct; 75(5):357-361. PubMed ID: 31007140 [TBL] [Abstract][Full Text] [Related]
20. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]